FGF23 and cardiovascular disorder: Furthermore, we also observed decreased levels of fibroblast growth factor 23 (FGF23) levels in the RCA group (p < 0.001 vs. heparin), remembering that FGF23 is a potent phosphate regulator associated with metabolic changes, endothelial dysfunction, and cardiovascular disease in renal patients (Table 2).